PROTAGONIST THERAPEUTICS INC(NASDAQ:PTGX) stock News

PTGX Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: ACCESS Newswire

Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis

22 days ago - By: Investor's Business Daily - Mentions: LLY NVO AZN PFE ...

Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?

22 days ago - By: ACCESS Newswire

Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity

a month ago - By: ACCESS Newswire

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate

a month ago - By: Yahoo Finance

Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity

2 months ago - By: Benzinga

9 Analysts Assess Protagonist Therapeutics: What You Need To Know

3 months ago - By: ACCESS Newswire

Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update

2 months ago - By: Takeda Pharmaceutical Company Limited - Mentions: TAK

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

2 months ago - By: Yahoo Finance - Mentions: DJT CMG BMO

Is Trump Media Stock a Buy After Dropping Over 50% From Its 52-Week High?

2 months ago - By: Yahoo Finance

Protagonist Therapeutics (PTGX) Rose on Positive Trial Outcome

4 months ago - By: ACCESS Newswire

Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025

2 months ago - By: ACCESS Newswire

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025

2 months ago - By: Zacks Investment Research - Mentions: BMY JNJ

J&J Oral Psoriasis Drug Meets Primary Goal in Late-Stage Study

2 months ago - By: Benzinga - Mentions: JNJ NVS

Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study

2 months ago - By: Yahoo Finance - Mentions: UNP POOL

Protagonist Therapeutics, Inc. (PTGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain

2 months ago - By: ACCESS Newswire

Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting

3 months ago - By: Zacks Investment Research - Mentions: CLSD

Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates

3 months ago - By: ACCESS Newswire

Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025

3 months ago - By: ACCESS Newswire

Protagonist Therapeutics Reports Granting of Inducement Award

3 months ago - By: ACCESS Newswire

Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill

4 months ago - By: Investor's Business Daily - Mentions: JNJ BMY

Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out

4 months ago - By: ACCESS Newswire

Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis

5 months ago - By: ACCESS Newswire

Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis

5 months ago - By: Takeda Pharmaceutical Company Limited - Mentions: TAK

PROTAGONIST THERAPEUTICS INC (PTGX) Stock News

PTGX Latest News, Press Relases and Analysis

Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis

Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?

Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate

Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity

9 Analysts Assess Protagonist Therapeutics: What You Need To Know

Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

Is Trump Media Stock a Buy After Dropping Over 50% From Its 52-Week High?

Protagonist Therapeutics (PTGX) Rose on Positive Trial Outcome

Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025

J&J Oral Psoriasis Drug Meets Primary Goal in Late-Stage Study

Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study

Protagonist Therapeutics, Inc. (PTGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain

Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting

Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates

Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025

Protagonist Therapeutics Reports Granting of Inducement Award

Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill

Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out

Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis

Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera